Accès gratuit
Numéro
Med Sci (Paris)
Volume 28, Numéro 5, Mai 2012
Page(s) 449 - 453
Section Nouvelles
DOI https://doi.org/10.1051/medsci/2012285002
Publié en ligne 30 mai 2012
  1. Yoshida K, Sanada M, Shiraishi Y, et al. Frequent pathway mutations of splicing machinery in myelodysplasia. Nature 2011 ; 478 : 64–69. [CrossRef] [PubMed] [Google Scholar]
  2. Papaemmanuil E, Cazzola M, Boultwood J, et al. Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts. N Engl J Med 2011 ; 365 : 1384–1395. [CrossRef] [PubMed] [Google Scholar]
  3. Graubert TA, Shen D, Ding L, et al. Recurrent mutations in the U2AF1 splicing factor in myelodysplastic syndromes. Nat Genet 2011 ; 44 : 53–57. [CrossRef] [PubMed] [Google Scholar]
  4. Patnaik MM, Lasho TL, Hodnefield JM, et al. SF3B1 mutations are prevalent in myelodysplastic syndromes with ring sideroblasts but do not hold independent prognostic value. Blood 2012 ; 119 : 569–572. [CrossRef] [PubMed] [Google Scholar]
  5. Damm F, Thol F, Kosmider O, et al. SF3B1 mutations in myelodysplastic syndromes: clinical associations and prognostic implications. Leukemia 2011 ; doi: 10.1038/leu.2011.321. [Google Scholar]
  6. Wang L, Lawrence MS, Wan Y, et al. SF3B1 and other novel cancer genes in chronic lymphocytic leukemia. N Engl J Med 2011 ; 365 : 2497–2506. [CrossRef] [PubMed] [Google Scholar]
  7. Quesada V, Conde L, Villamor N, et al. Exome sequencing identifies recurrent mutations of the splicing factor SF3B1 gene in chronic lymphocytic leukemia. Nat Genet 2011 ; 44 : 47–52. [CrossRef] [PubMed] [Google Scholar]
  8. Ferrando AA. The role of NOTCH1 signaling in T-ALL. Hematology Am Soc Hematol Educ Program 2009 : 353–361. [CrossRef] [Google Scholar]
  9. Di Ianni M, Baldoni S, Rosati E, et al. A new genetic lesion in B-CLL: a NOTCH1 PEST domain mutation. Br J Haematol 2009 ; 146 : 689–691. [CrossRef] [PubMed] [Google Scholar]
  10. Fabbri G, Rasi S, Rossi D, et al. Analysis of the chronic lymphocytic leukemia coding genome: role of NOTCH1 mutational activation. J Exp Med 2011 ; 208 : 1389–1401. [CrossRef] [PubMed] [Google Scholar]
  11. Puente XS, Pinyol M, Quesada V, et al. Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia. Nature 2011 ; 475 : 101–105. [CrossRef] [PubMed] [Google Scholar]
  12. Hiriart E, Gruffat H, Buisson M, et al. Interaction of the Epstein-Barr virus mRNA export factor EB2 with human Spen proteins SHARP, OTT1, and a novel member of the family, OTT3, links Spen proteins with splicing regulation and mRNA export. J Biol Chem 2005 ; 280 : 36935–36945. [CrossRef] [PubMed] [Google Scholar]
  13. Xu S, Powers MA. Nuclear pore proteins and cancer. Semin Cell Dev Biol 2009 ; 20 : 620–630. [CrossRef] [PubMed] [Google Scholar]
  14. Christofk HR, Vander Heiden MG, Harris MH, et al. The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth. Nature 2008 ; 452 : 230–233. [CrossRef] [PubMed] [Google Scholar]
  15. Gabut M, Samavarchi-Tehrani P, Wang X, et al. An alternative splicing switch regulates embryonic stem cell pluripotency and reprogramming. Cell 2011 ; 147 : 132–146. [CrossRef] [PubMed] [Google Scholar]
  16. Luco RF, Misteli T. More than a splicing code: integrating the role of RNA, chromatin and non-coding RNA in alternative splicing regulation. Curr Opin Genet Dev 2011 ; 21: 366–372. [CrossRef] [PubMed] [Google Scholar]
  17. Chapman MA, Lawrence MS, Keats JJ, et al. Initial genome sequencing and analysis of multiple myeloma. Nature 2011 ; 471 : 467–472. [CrossRef] [PubMed] [Google Scholar]
  18. Ding L, Ley TJ, Larson DE, et al. Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing. Nature 2012 ; 481 : 506–510. [CrossRef] [PubMed] [Google Scholar]
  19. Ebert BL. Molecular dissection of the 5q deletion in myelodysplastic syndrome. Semin Oncol 2011 ; 38 : 621–626. [CrossRef] [PubMed] [Google Scholar]
  20. Lasho TL, Finke CM, Hanson CA, et al. SF3B1 mutations in primary myelofibrosis: clinical, histopathology and genetic correlates among 155 patients. Leukemia 2011. [Google Scholar]
  21. Kikushige Y, Ishikawa F, Miyamoto T, et al. Self-renewing hematopoietic stem cell is the primary target in pathogenesis of human chronic lymphocytic leukemia. Cancer Cell 2011 ; 20 : 246–259. [CrossRef] [PubMed] [Google Scholar]
  22. Quivoron C, Couronne L, Della Valle V, et al. TET2 inactivation results in pleiotropic hematopoietic abnormalities in mouse and is a recurrent event during human lymphomagenesis. Cancer Cell 2011 ; 20 : 25–38. [CrossRef] [PubMed] [Google Scholar]
  23. Yokoi A, Kotake Y, Takahashi K, et al. Biological validation that SF3b is a target of the antitumor macrolide pladienolide. FEBS J 2011 ; 278 : 4870–4880. [CrossRef] [PubMed] [Google Scholar]
  24. Rossi D, Bruscaggin A, Spina V, et al. Mutations of the SF3B1 splicing factor in chronic lymphocytic leukemia: association with progression and fludarabine-refractoriness. Blood 2011 ; 118 : 6904–6908. [CrossRef] [PubMed] [Google Scholar]
  25. Bernard OA, Gilliland DG, Mercher T. Activation de la voie Notch par OTT-MAL dans les leucémies aiguës mégacaryoblastiques. Med Sci (Paris) 2009 ; 25 : 676–678. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  26. Mercher T, Quivoron C, Couronné L, et al. I In cauda venenum ou de l’importance de (la) TET(2). Med Sci (Paris) 2011 ; 27 : 1064–1066. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]

Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.

Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.

Le chargement des statistiques peut être long.